Dyne Therapeutics (DYN) Stock Forecast, Price Target & Predictions
DYN Stock Forecast
Dyne Therapeutics stock forecast is as follows: an average price target of $43.88 (represents a 54.56% upside from DYN’s last price of $28.39) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
DYN Price Target
The average price target for Dyne Therapeutics (DYN) is $43.88 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $18.00. This represents a potential 54.56% upside from DYN's last price of $28.39.
DYN Analyst Ratings
According to 8 Wall Street analysts, Dyne Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DYN stock is 1 'Strong Buy' (12.50%), 7 'Buy' (87.50%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Dyne Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Michael Ulz | Morgan Stanley | $52.00 | $43.64 | 19.16% | 83.16% |
| Aug 13, 2024 | Edward Tenthoff | Piper Sandler | $53.00 | $43.07 | 23.06% | 86.69% |
| Jun 24, 2024 | Eun Yang | Jefferies | $42.00 | $35.94 | 16.86% | 47.94% |
| Jun 17, 2024 | Francois Brisebois | Oppenheimer | $55.00 | $32.15 | 71.07% | 93.73% |
| May 21, 2024 | Keay Nakae | Chardan Capital | $42.00 | $35.38 | 18.71% | 47.94% |
| May 20, 2024 | Andrew Fein | H.C. Wainwright | $48.00 | $33.83 | 41.91% | 69.07% |
| May 20, 2024 | Paul Matteis | Stifel Nicolaus | $41.00 | $27.68 | 48.12% | 44.42% |
| Apr 30, 2024 | Michael Ulz | Morgan Stanley | $40.00 | $25.46 | 57.11% | 40.89% |
| Nov 29, 2022 | - | J.P. Morgan | $18.00 | $10.46 | 72.08% | -36.60% |
| Sep 06, 2022 | Edward Tenthoff | Piper Sandler | $23.00 | $11.60 | 98.28% | -18.99% |
The latest Dyne Therapeutics stock forecast, released on Aug 14, 2024 by Michael Ulz from Morgan Stanley, set a price target of $52.00, which represents a 19.16% increase from the stock price at the time of the forecast ($43.64), and a 83.16% increase from DYN last price ($28.39).
Dyne Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 8 |
| Avg Price Target | - | - | $46.63 |
| Last Closing Price | $28.39 | $28.39 | $28.39 |
| Upside/Downside | -100.00% | -100.00% | 64.25% |
In the current month, the average price target of Dyne Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Dyne Therapeutics's last price of $28.39. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Aug 14, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 17, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 20, 2024 | Jefferies | Buy | Buy | Hold |
| May 20, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Dyne Therapeutics's last stock rating was published by Piper Sandler on Sep 23, 2024. The company gave DYN a "Overweight" rating, the same as its previous rate.
Dyne Therapeutics Financial Forecast
Dyne Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | $1.67M |
| High Forecast | - | - | - | - | - | - | - | $1.67M |
| Low Forecast | - | - | - | - | - | - | - | $1.67M |
| # Analysts | - | - | - | - | - | - | - | 3 |
| Surprise % | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DYN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Dyne Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 3 |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict DYN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dyne Therapeutics's previous annual EBITDA (undefined) of $NaN.
Dyne Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 3 |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-91.95M | $-87.51M | $-85.48M | $-81.22M | $-84.72M | $-65.86M | $-66.39M | $-74.01M |
| High Forecast | $-91.95M | $-87.51M | $-85.48M | $-65.71M | $-64.24M | $-65.86M | $-66.39M | $-74.01M |
| Low Forecast | $-91.95M | $-87.51M | $-85.48M | $-95.82M | $-100.55M | $-65.86M | $-66.39M | $-74.01M |
| Surprise % | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DYN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Dyne Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 3 |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Dyne Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DYN last annual SG&A of $NaN (undefined).
Dyne Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 3 |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.99 | $-0.95 | $-0.92 | $-0.88 | $-0.92 | $-0.71 | $-0.72 | $-0.80 |
| High Forecast | $-0.99 | $-0.95 | $-0.92 | $-0.71 | $-0.69 | $-0.71 | $-0.72 | $-0.80 |
| Low Forecast | $-0.99 | $-0.95 | $-0.92 | $-1.04 | $-1.09 | $-0.71 | $-0.72 | $-0.80 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Dyne Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DYN previous annual EPS of $NaN (undefined).
Dyne Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PLRX | Pliant Therapeutics | $12.43 | $39.71 | 219.47% | Buy |
| ERAS | Erasca | $2.67 | $7.00 | 162.17% | Buy |
| MLYS | Mineralys Therapeutics | $11.48 | $30.00 | 161.32% | Buy |
| STOK | Stoke Therapeutics | $12.03 | $30.60 | 154.36% | Buy |
| CGEM | Cullinan Oncology | $13.86 | $31.50 | 127.27% | Buy |
| DSGN | Design Therapeutics | $5.80 | $9.67 | 66.72% | Buy |
| CYTK | Cytokinetics | $50.22 | $83.23 | 65.73% | Buy |
| DYN | Dyne Therapeutics | $28.39 | $43.88 | 54.56% | Buy |
| EWTX | Edgewise Therapeutics | $31.44 | $45.00 | 43.13% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.13 | $60.63 | 9.98% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |